BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zane LT, Hughes MH, Shakib S. Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers. Am J Clin Dermatol. 2016;17:519-526. [PMID: 27335049 DOI: 10.1007/s40257-016-0204-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Udkoff J, Waldman A, Ahluwalia J, Borok J, Eichenfield LF. Current and emerging topical therapies for atopic dermatitis. Clinics in Dermatology 2017;35:375-82. [DOI: 10.1016/j.clindermatol.2017.03.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
2 Ciaravino V, Coronado D, Lanphear C, Chanda S. 2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis. J Dermatol Sci 2017;87:116-22. [PMID: 28416366 DOI: 10.1016/j.jdermsci.2017.03.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
3 Fourzali K, Yosipovitch G. Safety considerations when using drugs to treat pruritus. Expert Opin Drug Saf 2020;19:467-77. [PMID: 32064980 DOI: 10.1080/14740338.2020.1728252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. Journal of the American Academy of Dermatology 2018;78:S43-52. [DOI: 10.1016/j.jaad.2017.11.056] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 13.7] [Reference Citation Analysis]
5 Hong JJ, Mosca ML, Hadeler EK, Brownstone ND, Bhutani T, Liao WJ. Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. Dermatol Ther (Heidelb) 2021;11:833-44. [PMID: 33914293 DOI: 10.1007/s13555-021-00536-6] [Reference Citation Analysis]
6 Demurtas A, Pescina S, Nicoli S, Santi P, Padula C. Development and validation of a simple method for the extraction and quantification of crisaborole in skin layers. Biomed Chromatogr 2019;33:e4664. [PMID: 31342550 DOI: 10.1002/bmc.4664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Hashim PW, Chima M, Kim HJ, Bares J, Yao CJ, Singer G, Chen T, Genece J, Baum D, Kimmel GW, Nia JK, Gagliotti M, Lebwohl MG. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial. J Am Acad Dermatol 2020;82:360-5. [PMID: 31279028 DOI: 10.1016/j.jaad.2019.06.1288] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
8 Diaz A, Guttman-Yassky E. Topical agents for the treatment of atopic dermatitis. Expert Rev Clin Immunol 2019;15:369-82. [PMID: 30587053 DOI: 10.1080/1744666X.2019.1564038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
9 Papier A, Strowd LC. Atopic dermatitis: a review of topical nonsteroid therapy. Drugs Context 2018;7:212521. [PMID: 29632548 DOI: 10.7573/dic.212521] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
10 Hon KLE, Chan VPY, Leung AKC. Experimental Drugs with the Potential to Treat Atopic Eczema. J Exp Pharmacol 2021;13:487-98. [PMID: 34012301 DOI: 10.2147/JEP.S259299] [Reference Citation Analysis]
11 Nguyen HL, Anderson KR, Tollefson MM. New and Emerging Therapies for Pediatric Atopic Dermatitis. Pediatr Drugs 2019;21:239-60. [DOI: 10.1007/s40272-019-00342-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
12 Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, Purohit VS, Zielinski MA, Vlahos B, Estrada YD, Saint-cyr Proulx E, Ports WC, Guttman-yassky E. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial. Journal of Allergy and Clinical Immunology 2019;144:1274-89. [DOI: 10.1016/j.jaci.2019.06.047] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 11.5] [Reference Citation Analysis]
13 Cheape AC, Murrell DF. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis. Expert Review of Clinical Immunology 2017;13:415-23. [DOI: 10.1080/1744666x.2017.1304820] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
14 Li H, Zuo J, Tang W. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol 2018;9:1048. [PMID: 30386231 DOI: 10.3389/fphar.2018.01048] [Cited by in Crossref: 129] [Cited by in F6Publishing: 92] [Article Influence: 43.0] [Reference Citation Analysis]
15 Renert-yuval Y, Guttman-yassky E. What’s New in Atopic Dermatitis. Dermatologic Clinics 2019;37:205-13. [DOI: 10.1016/j.det.2018.12.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 14.5] [Reference Citation Analysis]
16 Hoy SM. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis. Am J Clin Dermatol 2017;18:837-43. [DOI: 10.1007/s40257-017-0327-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
17 Mcdowell L, Olin B. Crisaborole: A Novel Nonsteroidal Topical Treatment for Atopic Dermatitis. Journal of Pharmacy Technology 2019;35:172-8. [DOI: 10.1177/8755122519844507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Davari DR, Nieman EL, McShane DB, Morrell DS. Current Perspectives on the Management of Infantile Atopic Dermatitis. J Asthma Allergy 2020;13:563-73. [PMID: 33177843 DOI: 10.2147/JAA.S246175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]